Michael Gelband’s Travere Therapeutics TVTX Stock Holding History

Michael Gelband’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.54M	Buy	97,442 +23,532	+32%	+$1.04M	0.04%	460
2026 Q1	$2.2M	Buy	+73,910	New	+$2.21M	0.02%	751
2025 Q4	–	Sell	-147,348	Closed	-$3.52M	–	2080
2025 Q3	$3.52M	Buy	147,348 +19,191	+15%	+$361K	0.04%	533
2025 Q2	$1.9M	Buy	+128,157	New	+$2.12M	0.02%	765
2024 Q1	–	Sell	-37,419	Closed	-$336K	–	1972
2023 Q4	$336K	Buy	+37,419	New	+$272K	﹤0.01%	1145
2023 Q3	–	Sell	-396,060	Closed	-$6.08M	–	2159
2023 Q2	$6.08M	Buy	+396,060	New	+$7.2M	0.05%	381
2023 Q1	–	Sell	-163,993	Closed	-$3.45M	–	2138
2022 Q4	$3.45M	Buy	+163,993	New	+$3.48M	0.05%	453
2022 Q1	–	Sell	-39,120	Closed	-$1.21M	–	2692
2021 Q4	$1.21M	Buy	+39,120	New	+$1.1M	0.01%	966
2021 Q1	–	Sell	-7,372	Closed	-$201K	–	2621
2020 Q4	$201K	Buy	+7,372	New	+$172K	﹤0.01%	1732
2020 Q1	–	Sell	-18,815	Closed	-$267K	–	1650
2019 Q4	$267K	Buy	18,815 +7,262	+63%	+$92.8K	0.01%	1209
2019 Q3	$134K	Buy	+11,553	New	+$191K	﹤0.01%	1201

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's TVTX Position: Q2 2026 in Review

Michael Gelband increased its Travere Therapeutics (TVTX) stake by 32% in Q2 2026, buying an estimated $1.04M and bringing the position to 97,442 shares worth $5.54M. The position accounts for 0.04% of the portfolio, ranked #460.

Michael Gelband first reported a position in TVTX in Q3 2019 and has held it in 11 quarters since. The position peaked at $6.08M in Q2 2023. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Michael Gelband held 97,442 shares of Travere Therapeutics worth $5.54M as of Q2 2026.
Michael Gelband bought 23,532 Travere Therapeutics shares in Q2 2026, an estimated $1.04M.
Travere Therapeutics made up 0.04% of Michael Gelband's portfolio in Q2 2026, its #460 holding.
Michael Gelband first reported a position in Travere Therapeutics in Q3 2019 and has held it in 11 quarters since.
Michael Gelband's Travere Therapeutics position peaked at $6.08M in Q2 2023.
317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.